267 related articles for article (PubMed ID: 33793049)
1. Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers.
Yamaguchi K; Matsumoto Y; Suzuki R; Nishida H; Omata D; Inaba H; Kukita A; Tanikawa M; Sone K; Oda K; Osuga Y; Maruyama K; Fujii T
Cancer Sci; 2021 Jun; 112(6):2493-2503. PubMed ID: 33793049
[TBL] [Abstract][Full Text] [Related]
2. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer.
Liu B; Han L; Liu J; Han S; Chen Z; Jiang L
Int J Nanomedicine; 2017; 12():955-968. PubMed ID: 28203075
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
Ma Y; Han J; Jiang J; Zheng Z; Tan Y; Liu C; Zhao Y
Life Sci; 2020 Dec; 262():118565. PubMed ID: 33038371
[TBL] [Abstract][Full Text] [Related]
5. Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin
Yokoe I; Omata D; Unga J; Suzuki R; Maruyama K; Okamoto Y; Osaki T
Drug Deliv; 2021 Dec; 28(1):530-541. PubMed ID: 33685314
[TBL] [Abstract][Full Text] [Related]
6. Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity.
Shim G; Lee S; Choi J; Lee S; Kim CW; Oh YK
Pharm Res; 2014 Aug; 31(8):2178-85. PubMed ID: 24562810
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
8. Localized controlled release of bevacizumab and doxorubicin by thermo-sensitive hydrogel for normalization of tumor vasculature and to enhance the efficacy of chemotherapy.
Darge HF; Andrgie AT; Hanurry EY; Birhan YS; Mekonnen TW; Chou HY; Hsu WH; Lai JY; Lin SY; Tsai HC
Int J Pharm; 2019 Dec; 572():118799. PubMed ID: 31678386
[TBL] [Abstract][Full Text] [Related]
9. The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.
Zabielska-Koczywąs K; Lechowski R
Molecules; 2017 Dec; 22(12):. PubMed ID: 29215573
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
11. pH-triggered echogenicity and contents release from liposomes.
Nahire R; Hossain R; Patel R; Paul S; Meghnani V; Ambre AH; Gange KN; Katti KS; Leclerc E; Srivastava DK; Sarkar K; Mallik S
Mol Pharm; 2014 Nov; 11(11):4059-68. PubMed ID: 25271780
[TBL] [Abstract][Full Text] [Related]
12. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
13. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake
Bellary A; Villarreal A; Eslami R; Undseth QJ; Lec B; Defnet AM; Bagrodia N; Kandel JJ; Borden MA; Shaikh S; Chopra R; Laetsch TW; Delaney LJ; Shaw CM; Eisenbrey JR; Hernandez SL; Sirsi SR
Theranostics; 2020; 10(18):8143-8161. PubMed ID: 32724463
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
Zhu F; Jiang Y; Luo F; Li P
J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional reduction-responsive SPIO&DOX-loaded PEGylated polymeric lipid vesicles for magnetic resonance imaging-guided drug delivery.
Wang S; Yang W; Du H; Guo F; Wang H; Chang J; Gong X; Zhang B
Nanotechnology; 2016 Apr; 27(16):165101. PubMed ID: 26941226
[TBL] [Abstract][Full Text] [Related]
18. PEGylated nano-graphene oxide as a nanocarrier for delivering mixed anticancer drugs to improve anticancer activity.
Pei X; Zhu Z; Gan Z; Chen J; Zhang X; Cheng X; Wan Q; Wang J
Sci Rep; 2020 Feb; 10(1):2717. PubMed ID: 32066812
[TBL] [Abstract][Full Text] [Related]
19. Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen.
Fang L; Kong SS; Zhong LK; Wang CM; Liu YJ; Ding HY; Sun J; Zhang YW; Li FZ; Huang P
Acta Pharmacol Sin; 2019 Apr; 40(4):539-545. PubMed ID: 29921887
[TBL] [Abstract][Full Text] [Related]
20. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
